KALA BIO receives Nasdaq deficiency notice for MVLS below $35M; 180 days to comply

KALA BIO, Inc.

Nasdaq notified KALA BIO on Nov 10, 2025 that MVLS was below $35M for 30 consecutive business days, violating Listing Rule 5550(b)(2).
Company also fails alternative standards: stockholders' equity <$2.5M and no net income from continuing operations in recent fiscal years.
Has until May 11, 2026 to regain compliance; if MVLS is at least $35M for 10 consecutive days, compliance is restored.
If not compliant by the deadline, stock subject to delisting; company may appeal to a Nasdaq Listing Qualifications Panel.

item 3.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-110316
form_type: 8-K
ticker: KALA
cik: 0001479419
company_name: KALA BIO, Inc.
filed_at: 2025-11-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.495348+00:00
generated_at: 2026-05-16T21:04:18.436669+00:00
sec_items: ["3.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-110316
json_url: https://secwatch.observer/filing/0001104659-25-110316.json
markdown_url: https://secwatch.observer/filing/0001104659-25-110316.md
text_url: https://secwatch.observer/filing/0001104659-25-110316.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465925110316/0001104659-25-110316-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465925110316/kala-20251110x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-110316

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.